<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Complement Altern Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Complement Altern Med</journal-id><journal-title-group><journal-title>BMC Complementary and Alternative Medicine</journal-title></journal-title-group><issn pub-type="epub">1472-6882</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28709452</article-id><article-id pub-id-type="pmc">5513038</article-id><article-id pub-id-type="publisher-id">1869</article-id><article-id pub-id-type="doi">10.1186/s12906-017-1869-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Influence of the patient-practitioner interaction context on acupuncture outcomes in functional dyspepsia: study protocol for a multicenter randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ko</surname><given-names>Seok-Jae</given-names></name><address><email>kokokoko119@hanmail.net</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Park</surname><given-names>Jae-Woo</given-names></name><address><email>pjw2907@khu.ac.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Leem</surname><given-names>Jungtae</given-names></name><address><email>julcho@naver.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kaptchuk</surname><given-names>Ted J.</given-names></name><address><email>ted_kaptchuk@hms.harvard.edu</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Napadow</surname><given-names>Vitaly</given-names></name><address><email>vitaly@nmr.mgh.harvard.edu</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kuo</surname><given-names>Braden</given-names></name><address><email>BKUO@mgh.harvard.edu</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Gerber</surname><given-names>Jessica</given-names></name><address><email>JGERBER2@mgh.harvard.edu</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Dimisko</surname><given-names>Laurie</given-names></name><address><email>LDIMISKO@mgh.harvard.edu</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Yeo</surname><given-names>Inkwon</given-names></name><address><email>inkwon@sookmyung.ac.kr</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lee</surname><given-names>Junhee</given-names></name><address><email>ssljh@khu.ac.kr</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kim</surname><given-names>Jinsung</given-names></name><address><email>oridoc@khu.ac.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 7818</institution-id><institution-id institution-id-type="GRID">grid.289247.2</institution-id><institution>Department of Gastroenterology, College of Korean Medicine, </institution><institution>Kyung Hee University, </institution></institution-wrap>26 Kyung Heedae-ro, Dongdaemun-gu, Seoul, 02447 Republic of Korea </aff><aff id="Aff2"><label>2</label>DongShin Korean Medicine Hospital, 351, Omok-ro, Yangcheon-gu, Seoul, 07999 Republic of Korea </aff><aff id="Aff3"><label>3</label>Program in Placebo Studies, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215 USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0386 9924</institution-id><institution-id institution-id-type="GRID">grid.32224.35</institution-id><institution/><institution>Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, </institution></institution-wrap>Medical School. Boston, Harvard, MA USA </aff><aff id="Aff5"><label>5</label>Gastroenterology Unit, Massachusetts General Hospital, Harvard Medical School, Blake 4, 55 Fruit St, Boston, MA 02114 USA </aff><aff id="Aff6"><label>6</label>BioMEMS Resource Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0729 3748</institution-id><institution-id institution-id-type="GRID">grid.412670.6</institution-id><institution>Department of Statistics, </institution><institution>Sookmyung Women&#x02019;s University, </institution></institution-wrap>100 Cheongpa-ro 47-gil, Yongsan-gu, Seoul, 04310 Republic of Korea </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 7818</institution-id><institution-id institution-id-type="GRID">grid.289247.2</institution-id><institution>Department of Sasang Constitutional Medicine, College of Korean Medicine, </institution><institution>Kyung Hee University, </institution></institution-wrap>26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447 Republic of Korea </aff></contrib-group><pub-date pub-type="epub"><day>14</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>17</volume><elocation-id>363</elocation-id><history><date date-type="received"><day>23</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>4</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">In the treatment of functional dyspepsia, the placebo effect has been reported to be high, and the influence of the patient-practitioner relationship may be a major component of this effect. The specific and non-specific effects of acupuncture cannot be easily distinguished, and the patient-practitioner relationship may influence the total therapeutic effect in clinical practice. There have been no studies that investigate the influence of patient-practitioner relationship on acupuncture treatment for patients with functional dyspepsia.</p></sec><sec><title>Methods</title><p id="Par2">Patients with postprandial distress syndrome, a functional dyspepsia subtype, will be recruited at three hospitals (two in Korea and one in USA) for an international, multi-center, randomized, patient/assessor-blinded, clinical trial. The total anticipated sample size is 88. The participants will be randomly allocated into two groups: an augmented interaction group and a limited interaction group. Acupuncture, with total 12 acupoints, will be performed twice weekly for 4 weeks in both groups. Trained practitioners will provide an &#x0201c;augmented&#x0201d; or &#x0201c;limited&#x0201d; interaction context, as determined by random allocation. The primary outcome measure is the proportion of responders, the proportion of participants who answer &#x0201c;yes&#x0201d; to more than half of the adequate relief questions during the study. Secondary outcome measures include questionnaires for quality of life and symptoms of dyspepsia, and maximum tolerable volume of nutrient drink test. Data will be collected at baseline and following 4 weeks of acupuncture.</p></sec><sec><title>Discussion</title><p id="Par3">This study will evaluate the influence of the patient-practitioner interaction on clinical effects of acupuncture in patients with functional dyspepsia.</p></sec><sec><title>Trial registration</title><p id="Par4">CRIS Identifier: (<ext-link ext-link-type="uri" xlink:href="http://cris.nih.go.kr">KCT0002229</ext-link>).</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Functional dyspepsia</kwd><kwd>Acupuncture</kwd><kwd>Randomized controlled trial</kwd><kwd>Augmented interaction</kwd><kwd>Limited interaction</kwd></kwd-group><funding-group><award-group><funding-source><institution>The Ministry of Health &#x00026; Welfare through the Korea Health Industry Development Institute (KHIDI)</institution></funding-source><award-id>HI13C0700</award-id><principal-award-recipient><name><surname>Lee</surname><given-names>Junhee</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par23">Functional dyspepsia (FD) describes various upper abdominal symptoms, including abdominal pain, fullness, early satiety, and epigastric burning, without organic disease [<xref ref-type="bibr" rid="CR1">1</xref>]. There is no cure for FD, and the therapeutic approach is complicated by the diversity of symptoms, and the inconsistency between symptoms and pathophysiology. While medication can be helpful in the short term, medication results in a temporary reduction of symptoms [<xref ref-type="bibr" rid="CR2">2</xref>]. As a result, patients with FD are turning to alternative and complementary medicine, such as acupuncture [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par24">The placebo effect is a non-specific improvement that occurs unrelated to the specific therapeutic regimen. Such non-specific clinical benefits can be divided into three components: the patient&#x02019;s response to observation and assessment (Hawthorne effect); the patient&#x02019;s response to the administration of a therapeutic regimen (placebo effect); and the patient&#x02019;s response to the patient-practitioner relationship [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. In patients with functional gastrointestinal disorders, up to 50% of the therapeutic effect may be due to the placebo effect [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. A study of patients with irritable bowel syndrome showed that non-specific effects could produce statistically and clinically significant outcomes, and that the patient-practitioner relationship was the most important component [<xref ref-type="bibr" rid="CR9">9</xref>]. In patients with gastroesophageal reflux disease, an expanded patient-practitioner visit resulted in greater improvement of symptoms, when compared to a standard empathic medical visit. Complementary and integrative medicine consultations may enhance the placebo effect [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par25">Specific effect and non-specific effects cannot be easily distinguished in complementary and integrative medicine. The influence of the patient-practitioner relationship could be a meaningful component of therapeutic experience. Therefore, to enhance the effect of treatment in a clinical setting, understanding the patient-practitioner relationship is required. To date, there have been no studies investigating the influence of patient-practitioner relationship on acupuncture treatment for patients with functional dyspepsia.</p><p id="Par26">This study is designed to investigate the cognitive, emotional, and symbolic contextual factors embedded in the patient-practitioner relationship. These factors are assumed to modulate, and potentially amplify, the effect of acupuncture. Contextual factors include the use of emphatic attention, natural expressions of warmth and support, positive expectations, attentive listening, thoughtful silence, and appropriate touch. We believe that a patient-practitioner relationship &#x0201c;augmented&#x0201d; with positive components will more intensely modulate emotion, cognition, and reward when compared to &#x0201c;limited&#x0201d; context treatments.</p><p id="Par27">Acupuncture is a suitable intervention to determine whether an expanded patient-practitioner interaction affects medical outcomes. The therapeutic encounter with acupuncture is &#x0201c;holistic,&#x0201d; since it includes the physical, mental/emotional, and spiritual dimensions of the individual. Therefore, acupuncture provides a suitable framework for an enhanced interaction. The acupuncture assessment interview can be adapted to extensively engage in physical, emotional, cognitive, existential, and social discourse, and can provide the patient with a sense of being cared for and understood.</p><p id="Par28">The goal of this study is to investigate the influence of the patient-practitioner relationship on the effect of acupuncture on symptoms of patients with functional dyspepsia. We will answer the questions:<list list-type="order"><list-item><p id="Par29"> What is the role for acupuncture in functional dyspepsia?</p></list-item><list-item><p id="Par30"> What are the underlying mechanisms of acupuncture&#x02019;s holistic clinical encounter? We will also compare the non-specific effects between Asian patients, who are likely familiar with acupuncture, and Western patients, through studies in both Asia and USA.</p></list-item></list>
</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Design</title><p id="Par31">This study is planned as a multicenter, randomized controlled, patient/assessor-blinded, clinical trial to investigate the effect of two different patient-practitioner interactions on symptoms, and quality of life, of patients with functional dyspepsia. This study will be conducted in Kyung Hee University Hospital at Gangdong, Kyung Hee University Medical Center (Seoul, Republic of Korea), and the Massachusetts General Hospital (Boston, MA, USA), from January 2017 to May 2018. Participants will be randomized in a 1:1 fashion to receive either an augmented or limited medical visit. All participants will be treated for functional dyspepsia by acupuncture for 4 weeks (8 sessions). Symptoms and quality of life will be measured by questionnaires. The practitioner will discuss patient problems, including dyspeptic symptoms, at each visit in either the augmented or limited format. The initial visit will be video recorded after obtaining the participants&#x02019; consent. The Clinical Trial Institutional Review Board (IRB) of Kyung Hee University Hospital at Gangdong (No. KHNMCOH 2016&#x02013;04&#x02013;007-001), Kyung Hee University Medical Center (No. KOMCIRB &#x02013; 150,914 &#x02013; HR-040), and Massachusetts General Hospital (No. 2016P001981/PHS) have approved the study. The study will be carried out in accordance with the standards of the International Committee on Harmonization on Good Clinical Practice, and the revised version of the Declaration of Helsinki. This study has been registered under the identifier No. KCT0002229 at CRIS (<ext-link ext-link-type="uri" xlink:href="http://cris.nih.go.kr">http://cris.nih.go.kr</ext-link>). Figure <xref rid="Fig1" ref-type="fig">1</xref> provides a study flow chart.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow chart of the study</p></caption><graphic xlink:href="12906_2017_1869_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec4"><title>Participants</title><p id="Par32">A total of 88 patients will be recruited from three centers (Kyung Hee University Hospital at Gangdong, 29 patients; Kyung Hee University Medical Center, 30 patients; and Massachusetts General Hospital, 29 patients).</p></sec><sec id="Sec5"><title>Inclusion and exclusion criteria</title><sec id="Sec6"><title>Inclusion criteria</title><p id="Par33">Patients who meet all of the following criteria will be considered for enrollment. The inclusion criteria are:<list list-type="order"><list-item><p id="Par34"> Age between 20 and 65&#x000a0;years.</p></list-item><list-item><p id="Par35"> Meeting the definition of functional dyspepsia, and postprandial distress syndrome, as a subtype of FD, according to the Rome III criteria [<xref ref-type="bibr" rid="CR1">1</xref>].</p></list-item><list-item><p id="Par36"> A degree of dyspepsia more than 40 points on the visual analogue scale (0, no symptoms; 100, the most severe symptoms).</p></list-item><list-item><p id="Par37"> Individuals who agreed not to begin new treatments associated with FD during the study. Participants may continue FD prescriptions, over the counter or alternative medications, and any psychological treatments, as long as they have been on a stable regimen for 30&#x000a0;days prior to the start of the study. Participants also agree not to change medications or dosage during the study.</p></list-item><list-item><p id="Par38"> Voluntarily agreed and sign an informed consent form.</p></list-item></list>
</p></sec><sec id="Sec7"><title>Exclusion criteria</title><p id="Par39">Exclusion criteria include:<list list-type="order"><list-item><p id="Par40"> Recent abnormal esophagogastroduodenoscopy or evidence of any organic diseases affecting gastrointestinal tract (e.g. erosive esophagitis, peptic ulcer, dysplasia, mucosa-associated, lymphoid tissue lymphoma, esophageal cancer, or gastric cancer).</p></list-item><list-item><p id="Par41"> Signs of irritable bowel syndrome.</p></list-item><list-item><p id="Par42"> Serious symptoms, including weight loss, black or tarry stool, or dysphagia.</p></list-item><list-item><p id="Par43"> Cardiac, pulmonary, hepatic or renal disease, or mental illness.</p></list-item><list-item><p id="Par44"> Gastrointestinal surgery, except for appendectomy performed more than 6 monthsprior to the study.</p></list-item><list-item><p id="Par45"> Women who are pregnant or breastfeeding.</p></list-item><list-item><p id="Par46"> Individuals taking drugs that could affect the gastrointestinal tract. A minimum washout period of 2 weeks is required before participating in the trial.</p></list-item><list-item><p id="Par47"> Participation in another clinical trial within 1 month of this trial.</p></list-item><list-item><p id="Par48"> Positive for human immunodeficiency virus infection.</p></list-item><list-item><p id="Par49"> Individuals taking herbal medicine or an oriental remedy for dyspepsia, or drugs that are considered inappropriate for this study.</p></list-item><list-item><p id="Par50"> Difficulties in attending the trial (e.g., paralysis, serious mental illness, dementia, drug addiction, time constraints, severe disorders of vision or hearing, illiteracy, etc.). Patients who have severe depression (more than 24 points in Beck Depression Inventory) will be excluded [<xref ref-type="bibr" rid="CR11">11</xref>].</p></list-item><list-item><p id="Par51"> Other issues that could interfere with acupuncture treatment (e.g., clotting disorders, leukopenia, pacemaker, epilepsy, or anticoagulant therapy).</p></list-item></list>
</p></sec></sec><sec id="Sec8"><title>Recruitment procedures</title><p id="Par52">Participants will be recruited in hospital outpatient clinics; by banner advertisements placed on the notice boards in the local communities; advertisements in the local newspaper, bus, and subway stations; and advertisements on web sites visited by patients with digestive diseases. Patients interested in participating will contact the Clinical Research Coordinator for further information. Patients will be screened for eligibility by a telephone interview and scheduled for an initial visit for serologic test including white blood cell, hemoglobin, hematocrit, platelet, <ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/Aspartate_transaminase">aspartate transaminase</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/Alanine_transaminase">alanine transaminase</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://www.google.co.kr/url?url=https://labtestsonline.org/understanding/analytes/bun/tab/faq/&#x00026;rct=j&#x00026;frm=1&#x00026;q=&#x00026;esrc=s&#x00026;sa=U&#x00026;ved=0ahUKEwi31dX2rt_RAhVJKJQKHQakBqQQFggeMAE&#x00026;usg=AFQjCNFYu3y24q3aIcomQH_lA0urKWZgLg">blood urea nitrogen</ext-link>, and creatinine test. After being fully informed about the procedures and risks, and given sufficient time to make a decision, participants who are deemed eligible will provide written, informed consent. Participants have the right to withdraw from the trial at any time during the study period.</p></sec><sec id="Sec9"><title>Randomization, allocation concealment, and blinding</title><p id="Par53">After participants have completed a baseline evaluation, they will be randomized to two groups: the augmented group and the limited group. The randomization will be carried out using random number lists, created in accordance with the PROC PLAN of SAS 9.4 (SAS Institute Inc., Cary, NC, USA) by an independent statistician. The acupuncture practitioner will be unaware of the allocation until opening an opaque, sealed envelope. Participants will not be informed that we are studying the patient-practitioner interaction. They will be told the study is "Acupuncture for the treatment of functional dyspepsia: An international multicenter trial." Participants will be informed of the purpose of the study in a debriefing session at the end of the study. The Clinical Research Coordinator evaluating the variables will be blinded to the allocation.</p></sec><sec id="Sec10"><title>Intervention</title><sec id="Sec11"><title>Augmented group</title><p id="Par54">The augmented group intervention contains two of components. First, a holistic assessment based on Traditional Korean Medicine in which the practitioner will discuss physical, psycho-emotional, social, and existential/spiritual parameters. Second, specific context enhancements, such as warmth and support, empathic attention, attentive listening, thoughtful silence, shared explanation and exploration of meaning, positive expectation, and therapeutic touch, including pulse and tongue evaluation. Many of these context enhancements are included in acupuncture practitioners&#x02019; style of treatment.</p><p id="Par55">In the augmented interaction group, in addition to questions about FD symptoms, the practitioner will explore the emotional experience of FD, and the meaning of FD as a condition experienced by the patient. As part of the interview process, the practitioner will engage in the seven specific enhancements. The use of these specific enhancements will occur at different times, in as natural a way as possible.</p></sec><sec id="Sec12"><title>Limited group</title><p id="Par56">The limited group will be conducted like a serious scientific encounter. It is meant to provide limited patient-practitioner interaction, and to evaluate the impact of the intervention in isolation from other context effects. Palpation of the pulse and abdominal examination will not be done. Practitioners will not explore the emotional experience, or the meaning of the illness. Furthermore, practitioners will not engage in any of the context enhancements, but will engage the patient as naturally as possible with a &#x0201c;matter of fact&#x0201d; and &#x0201c;to-the-point&#x0201d; demeanor.</p><p id="Par57">The practitioner will read a script to the patient explaining that the patient-practitioner interaction must to be kept to a minimum because of the scientific nature of a randomized controlled trial. Subsequent treatment sessions will be performed within the limits defined in the first session, thus the context will remain restricted. The acupuncture treatment will take 20&#x000a0;min and will involve no additional communication between practitioner and patient.</p><p id="Par58">While maintaining a personable and reassuring demeanor, the practitioner will avoid engaging in education or reframing of the participant&#x02019;s pain or condition, and will avoid any verbal interaction, other than that necessary to evaluate the participant&#x02019;s initial condition, change, and progress. The practitioner will strive to maintain a natural and comfortable interaction with the patient, as to not compromise the validity of the treatment. The differences between the augmented and limited groups are detailed in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Guideline for augmented and limited interaction context</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Augmented Interaction context</th><th>Limited Interaction context</th></tr></thead><tbody><tr><td>1. Warm, Friendly Style</td><td>1. Neutral, Impersonal Style</td></tr><tr><td>&#x02003;- Shake hands<break/>&#x02003;- Thank patient for participation in study<break/>&#x02003;- Frequent use of patient&#x02019;s name.<break/>&#x02003;- Sit face to face, not separated by a desk<break/>&#x02003;- Appropriate smiling<break/>&#x02003;- Appropriate use of humor</td><td>&#x02003;- Do not initiate hand shaking<break/>&#x02003;- Do not thank patient for participation<break/>&#x02003;- Infrequent use of patient&#x02019;s name<break/>&#x02003;- Sit separated by desk<break/>&#x02003;- Limit smiling<break/>&#x02003;- Avoid humor</td></tr><tr><td>2. Attentive</td><td>2. Distracted</td></tr><tr><td>&#x02003;- Frequent eye contact<break/>&#x02003;- Leans in at appropriate points<break/>&#x02003;- Appropriate use of head nods<break/>&#x02003;- Limited use of computer or clipboard</td><td>&#x02003;- Infrequent eye contact<break/>&#x02003;- Bodily posture conveys distance<break/>&#x02003;- Minimal use of head nods<break/>&#x02003;- Frequent use of computer or clipboard</td></tr><tr><td>3. Active Listening</td><td>3. Minimal Active Listening</td></tr><tr><td>&#x02003;- Open-ended questions that emphasize patient&#x02019;s experience of illness<break/>&#x02003;- Avoid interrupting patient<break/>&#x02003;- Patient speaks more than clinician<break/>&#x02003;- Allow some silence for contemplation<break/>&#x02003;- Reflections<break/>&#x02003;- Clarifications</td><td>&#x02003;- Closed-ended questions (yes or no)<break/>&#x02003;- Tightly focused on review of systems<break/>&#x02003;- Interrupt patient to keep to script<break/>&#x02003;- Clinician does most of the talking<break/>&#x02003;- Fill silences quickly<break/>&#x02003;- Avoid reflections<break/>&#x02003;- Avoid clarifications</td></tr><tr><td>4. Personalized Content</td><td>4. Generic Content</td></tr><tr><td>&#x02003;- The clinician will encourage the patient to speak for the majority of the time<break/>&#x02003;- The clinician&#x02019;s explanation of the illness and treatment will be personalized, using the patient&#x02019;s own words wherever possible</td><td>&#x02003;- The clinician will dominate the interview, speaking for the majority of the time<break/>&#x02003;- The clinician&#x02019;s explanation of the illness and treatment will be generic with no personalization for the patient</td></tr><tr><td>5. Empathic Connection</td><td>5. Reduced Empathy and Connection</td></tr><tr><td>&#x02003;- Partnership (We&#x02019;ll work together)<break/>&#x02003;- Empathy (That must have been painful)<break/>&#x02003;- Validate emotions</td><td>&#x02003;- No expression of partnership<break/>&#x02003;- No empathy expression (but not callousness)<break/>&#x02003;- Avoid emotional content</td></tr><tr><td>6. Mirroring</td><td>6. No Mirroring</td></tr><tr><td>&#x02003;- Mirror patient&#x02019;s prosody (volume, pace, intonation)<break/>&#x02003;- Avoid medical jargon<break/>&#x02003;- Use vocabulary familiar to patient</td><td>&#x02003;- No effort at mirroring patient&#x02019;s prosody<break/>&#x02003;- Use medical jargon<break/>&#x02003;- No effort to use vocabulary familiar to patient</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec13"><title>Treatment fidelity</title><p id="Par59">In order to evaluate compliance with the protocol and treatment fidelity, the first acupuncture session for all subjects will be videotaped. Ten percent (10%) of videotapes will be randomly reviewed to assure that the practitioners in the augmented and limited groups follow the standard operating procedure. Patients will be made aware of the recording as part of the informed consent process, and only the interview will be recorded. Participants will be told that the purpose of the recording is to assure practitioners compliance with the protocol. Videotaping of treatment will not be performed, and the practitioner will assure that the video is turned off when the acupuncture treatment starts.</p></sec><sec id="Sec14"><title>Acupuncture treatment</title><p id="Par60">Acupuncture will be applied in the same manner in both groups. A total of 12 acupoints (Hegu [LI 4], Zusanli [ST 36], Taichong [LR 3], Quze [PC 3], Gongsun [SP 4] and Liangqiu [ST 34] bilaterally) will be used twice weekly for 4&#x000a0;week (8 sessions). Acupuncture will be performed as follows. The acupuncture needle will be applied to the participant&#x02019;s skin. Then, after turning on the timer, the acupuncture needles will be rotated right and left for 3 s at each acupoint (total 12 acupoints). After 20&#x000a0;min, the timer is turned off, and the acupuncture needles will be rotated right and left for another 3 s at each acupoint, and then the acupuncture needles will be removed.</p><p id="Par61">Detailed information regarding the acupuncture rationale is described in the revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) [<xref ref-type="bibr" rid="CR12">12</xref>] shown in Table <xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Acupuncture treatment details based on the STRICTA (Macpherson H et al., [<xref ref-type="bibr" rid="CR12">12</xref>]) checklist</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Item</th><th>Detail</th></tr></thead><tbody><tr><td rowspan="3">1. Acupuncture rationale</td><td>1a) Style of acupuncture<break/>&#x02003;&#x02003;- Manual acupuncture based on traditional meridian theory.</td></tr><tr><td>1b) Reasoning for treatment provided, based on historical context, literature sources, and/or consensus methods, with references where appropriate<break/>&#x02003;&#x02003;- Based on the traditional meridian theory, clinical experience, and consensus by the experts in acupuncture and FD.</td></tr><tr><td>1c) Extent to which treatment was varied<break/>&#x02003;&#x02003;- No additional acupoints allowed.</td></tr><tr><td rowspan="7">2. Details of needling</td><td>2a) Number of needle insertions per subject per session (mean and range where relevant)<break/>&#x02003;&#x02003;- Fixed 12 acupoints.</td></tr><tr><td>2b) Names (or location if no standard name) of points used (uni/bilateral)<break/>&#x02003;&#x02003;- LI 4, ST36, LR3, PC3, SP4 and ST34 (bilateral)</td></tr><tr><td>2c) Depth of insertion, based on a specified unit of measurement, or on a particular tissue level<break/>&#x02003;&#x02003;- From 5 to 30&#x000a0;mm.</td></tr><tr><td>2d) Response sought (e.g. de qi or muscle twitch response)<break/>&#x02003;&#x02003;- &#x02018;De qi&#x02019; sensation</td></tr><tr><td>2e) Needle stimulation (e.g. manual, electrical)<break/>&#x02003;&#x02003;- Manual acupuncture</td></tr><tr><td>2f) Needle retention time<break/>&#x02003;&#x02003;- Twenty minutes.</td></tr><tr><td>2g) Needle type (diameter, length, and manufacturer or material)<break/>&#x02003;&#x02003;- A sterilized stainless steel needle (0.25&#x000a0;&#x000d7;&#x000a0;40&#x000a0;mm, DONGBANG ACUPUNCTURE INC., Ungcheon, Boryeong, Korea).</td></tr><tr><td rowspan="2">3. Treatment regimen</td><td>3a) Number of treatment sessions<break/>&#x02003;&#x02003;- Eight sessions.</td></tr><tr><td>3b) Frequency and duration of treatment sessions<break/>&#x02003;&#x02003;- Twice weekly for 4&#x000a0;weeks, 20&#x000a0;min for each session.</td></tr><tr><td rowspan="2">4. Other components of treatment</td><td>4a) Details of other interventions administered to the acupuncture group (e.g. moxibustion, cupping, herbs, exercises, lifestyle advice)<break/>&#x02003;&#x02003;- Advice for lifestyle habit included and no other interventions during the study allowed.</td></tr><tr><td>4b) Setting and context of treatment, including instructions to practitioners, and information and explanations to patients<break/>&#x02003;&#x02003;- Participants will be informed that the acupuncture treatment is based on traditional Korean Medicine and previous studies on clinical trial.</td></tr><tr><td>5. Practitioner background</td><td>5) Description of participating acupuncturists (qualification or professional affiliation, years in acupuncture practice, other relevant experience)<break/>&#x02003;&#x02003;- Korean Medicine Doctors who have license and at least 2&#x000a0;years of experience of treating gastrointestinal diseases. They have studied acupuncture for more than 10&#x000a0;years and graduated university of Korean medicine. To ensure providing identical treatments, they finished 10&#x000a0;h of training and simulated the protocol.</td></tr><tr><td rowspan="2">6. Control or comparator interventions</td><td>6a) Rationale for the control or comparator in the context of the research question, with sources that justify this choice<break/>&#x02003;&#x02003;- No control intervention</td></tr><tr><td>6b) Precise description of the control or comparator. If sham acupuncture or any other type of acupuncture-like control is used, provide details as for Items 1 to 3 above.</td></tr></tbody></table><table-wrap-foot><p>
<italic>LI</italic> Large intestine meridian, <italic>ST</italic> Stomach meridian, <italic>LR</italic> Liver meridian, <italic>PC</italic> Pericardium meridian, <italic>SP</italic> Spleen meridian</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec15"><title>Outcome measurements</title><sec id="Sec16"><title>Primary outcome</title><sec id="FPar1"><title>Proportion of responder</title><p id="Par62">Proportion of responder (PR) will be used to evaluate the proportion of patients who showed alleviation of FD symptoms, with relief of stomach pain or discomfort. PR is defined as the proportion of participants who answer &#x0201c;yes&#x0201d; to the adequate relief question more than half the time during the treatment period. The adequate relief question is, "After the last visit, have you had adequate relief of your stomach pain or discomfort?" The adequate relief question will be asked at every visit, starting with the second visit. PR will be calculated for the 4-week period. This indicator has been applied in several studies with functional intestinal diseases [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p></sec></sec><sec id="Sec17"><title>Secondary outcomes</title><sec id="FPar2"><title>Nepean dyspepsia index</title><p id="Par63">The Nepean Dyspepsia Index (NDI) was validated by Talley et al. [<xref ref-type="bibr" rid="CR15">15</xref>] and is a reliable index to measure the degree of dyspeptic symptoms, and the quality of life. Lee et al. developed the Korean version of the NDI [<xref ref-type="bibr" rid="CR16">16</xref>]. Although, the NDI is composed of two categories, in this study, we will use only the symptom-based questions covering the period, severity, and degree of distress of 15 symptoms.</p></sec><sec id="FPar3"><title>Short form 36-item health survey</title><p id="Par64">The Short Form 36-item Health Survey (SF-36) is a self-report health status measure, that provides information about the overall health of the individual, and includes physical, mental, and social health [<xref ref-type="bibr" rid="CR17">17</xref>]. The Korean version of SF-36 has undergone comprehensive psychometric evaluation of reliability and validity [<xref ref-type="bibr" rid="CR18">18</xref>].</p></sec><sec id="FPar4"><title>The state-trait anxiety inventory</title><p id="Par65">The State-Trait Anxiety Inventory (STAI) [<xref ref-type="bibr" rid="CR19">19</xref>] investigates anxiety as a psychological factor. The STAI is a questionnaire composed of the following 40 items evaluated using a 4-point Likert scale: 20 items evaluate the state of anxiety (anxiety triggered by a specific event) and 20 items identify the trait of anxiety (anxiety derived from personal characteristics). Higher scores indicate more severe anxiety. Anxiety has a significant correlation with dyspepsia [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], and the effect of acupuncture on anxiety will be evaluated using the STAI.</p></sec><sec id="FPar5"><title>Visual analog scale for dyspepsia</title><p id="Par66">Participants will be requested to check the intensity of their abdominal discomfort on 0 to 100 numerical rating scale, with 0 representing &#x0201c;no discomfort&#x0201d; and 100 representing "the most intense discomfort he/she ever had".</p></sec><sec id="FPar6"><title>Expectations for relief scale</title><p id="Par67">This scale evaluates the degree of the patients&#x02019; expectations for the treatment. Subjects will be asked two questions, "How bothersome do you expect your dyspepsia to be at the end of treatment?" and "How much do you expect acupuncture treatment will relieve your clinical dyspepsia?" Participants will be asked to indicate their responses on a 0 to 100 numerical rating scale.</p></sec><sec id="FPar7"><title>Massachusetts General Hospital acupuncture sensation scale</title><p id="Par68">The descriptors in the &#x0201c;Subjective Acupuncture Sensation Scale&#x0201d; resulting in the Massachusetts General Hospital Acupuncture Sensation Scale (MASS) were expanded by Kong et al. [<xref ref-type="bibr" rid="CR22">22</xref>]. The MASS includes soreness, aching, deep pressure, heaviness, fullness/distension, tingling, numbness, sharp pain, dull pain, warmth, cold, throbbing, and a blank row for subjects to describe their perceptions in their own words. Establishment of the MASS involved extensive review of the relevant literature and it is the most comprehensive assessment tool in measuring the needle sensations.</p></sec><sec id="FPar8"><title>The consultation and relational empathy measure</title><p id="Par69">The Consultation and Relational Empathy (CARE) measure was originally developed to assess empathy between doctor and patient. Mercer et al. [<xref ref-type="bibr" rid="CR23">23</xref>] confirmed the reliability and validity. The CARE measure consists of 10 questions, and each question has six options from &#x0201c;poor&#x0201d; to &#x0201c;excellent&#x0201d; and &#x0201c;does not apply.&#x0201d;</p></sec><sec id="FPar9"><title>Interpersonal reactivity index</title><p id="Par70">Interpersonal Reactivity Index (IRI) investigates the degree of empathy defined as the "reactions of one individual to the observed experiences of another" [<xref ref-type="bibr" rid="CR24">24</xref>]. The IRI consists of 28-items answered on a 5-point Likert scale, ranging from &#x0201c;Does not describe me well&#x0201d; to &#x0201c;Describes me very well.&#x0201d; The measure has four subscales, each containing seven different items. These subscales are: Perspective Taking, the tendency to spontaneously adopt the psychological point of view of others; Fantasy, taps the respondents&#x02019; tendencies to transpose themselves imaginatively into the feelings and actions of fictitious characters in books, movies, and plays; Empathic Concern, assesses &#x0201c;other-oriented&#x0201d; feelings of sympathy and concern for unfortunate others; and Personal Distress, measures &#x0201c;self-oriented&#x0201d; feelings of personal anxiety and unease intense interpersonal settings. Korean version of IRI was validated by Kang et al. [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="FPar10"><title>Maximum tolerable volume</title><p id="Par71">This outcome is recorded as part of the validated nutrient drink test [<xref ref-type="bibr" rid="CR26">26</xref>]. It is designed to induce dyspepsia, by ingesting a standard meal. When compared to a barium meal radiograph study, it is simple, non-invasive assessment that has been widely used [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. After an overnight fast, participants will consume a canned drink (Ensure, 237&#x000a0;ml/can, Abbott Nutrition, Columbus, Ohio, USA), at a constant rate, until they reach the maximum level of fullness. At five-minute intervals, the subjects will verbally rate their overall fullness level, on a scale of 0 to 5 (0, threshold; 5, maximum satiety). Participants will be instructed to stop drinking when their fullness level reaches 5. The actual volume consumed is the maximum tolerable volume. Questionnaires for postprandial symptoms and intensity of abdominal discomfort will be administered 30&#x000a0;min after drinking. If participants cannot continue to consume the test drinks, for any reason, they can voluntarily stop at any time.</p></sec><sec id="FPar11"><title>The pictorial representation of illness and self measure</title><p id="Par72">The Pictorial Representation of Illness and Self Measure (PRISM) is a two dimensional pictorial method to assess the burden of suffering. The burden of suffering is defined as "a state of severe distress associated with events that threaten the intactness of the person." Patients illustrate their burden of suffering by the distance from &#x0201c;self&#x0201d; to an illness circle, where a shorter distance indicates a higher burden of suffering. The PRISM has been validated as a reliable method for assessing the burden of suffering in a variety of chronic diseases [<xref ref-type="bibr" rid="CR29">29</xref>].</p></sec></sec><sec id="Sec18"><title>Participant timeline</title><p id="Par73">The time schedule of enrollment, intervention, and assessments is summarized in Table <xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table 3</label><caption><p>The schedule of enrollment, intervention, and assessments</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study period</th><th>Screening<break/>Visit</th><th colspan="8">Acupuncture treatment period</th></tr><tr><th>Visit</th><th/><th>v1</th><th>v2</th><th>v3</th><th>v4</th><th>v5</th><th>v6</th><th>v7</th><th>v8</th></tr><tr><th>Week</th><th/><th>1</th><th>1</th><th>2</th><th>2</th><th>3</th><th>3</th><th>4</th><th>4</th></tr></thead><tbody><tr><td>Patients</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Informed Consent</td><td>&#x0221a;</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Demographics</td><td>&#x0221a;</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Physical examination</td><td>&#x0221a;</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;History Examination</td><td>&#x0221a;</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Dyspepsia History Examination</td><td>&#x0221a;</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Inclusion/Exclusion Criteria</td><td>&#x0221a;</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Serologic test/ Evaluation</td><td>&#x0221a;</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;BDI</td><td>&#x0221a;</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Randomization</td><td>&#x0221a;</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Trial evaluation</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Investigation of Concomitant medication</td><td/><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td></tr><tr><td>&#x02003;Adverse events</td><td/><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td></tr><tr><td>Outcomes</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;AR of abdominal pain &#x00026; discomfort</td><td/><td/><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td><td>&#x0221a;<sup>*</sup>
</td></tr><tr><td>&#x02003;VAS for dyspepsia</td><td>&#x0221a;</td><td>&#x0221a;<sup>*</sup>
</td><td/><td/><td/><td/><td/><td/><td>&#x0221a;<sup>&#x02020;</sup>
</td></tr><tr><td>&#x02003;Expectations for Relief Scale</td><td/><td>&#x0221a;<sup>*</sup>
</td><td/><td/><td>&#x0221a;<sup>*</sup>
</td><td/><td/><td/><td>&#x0221a;<sup>*</sup>
</td></tr><tr><td>&#x02003;MASS</td><td/><td>&#x0221a;<sup>&#x02020;</sup>
</td><td>&#x0221a;<sup>&#x02020;</sup>
</td><td>&#x0221a;<sup>&#x02020;</sup>
</td><td>&#x0221a;<sup>&#x02020;</sup>
</td><td>&#x0221a;<sup>&#x02020;</sup>
</td><td>&#x0221a;<sup>&#x02020;</sup>
</td><td>&#x0221a;<sup>&#x02020;</sup>
</td><td>&#x0221a;<sup>&#x02020;</sup>
</td></tr><tr><td>&#x02003;The CARE measure</td><td/><td>&#x0221a;<sup>&#x02020;</sup>
</td><td/><td/><td/><td/><td/><td/><td>&#x0221a;<sup>&#x02020;</sup>
</td></tr><tr><td>&#x02003;IRI</td><td/><td>&#x0221a;<sup>&#x02020;</sup>
</td><td/><td/><td/><td/><td/><td/><td>&#x0221a;<sup>&#x02020;</sup>
</td></tr><tr><td>&#x02003;NDI</td><td/><td>&#x0221a;<sup>*</sup>
</td><td/><td/><td/><td/><td/><td/><td>&#x0221a;<sup>&#x02020;</sup>
</td></tr><tr><td>&#x02003;SF-36</td><td/><td>&#x0221a;<sup>*</sup>
</td><td/><td/><td/><td/><td/><td/><td>&#x0221a;<sup>&#x02020;</sup>
</td></tr><tr><td>&#x02003;STAI</td><td/><td>&#x0221a;<sup>*</sup>
</td><td/><td/><td/><td/><td/><td/><td>&#x0221a;<sup>&#x02020;</sup>
</td></tr><tr><td>&#x02003;PRISM</td><td/><td>&#x0221a;<sup>*</sup>
</td><td/><td/><td/><td/><td/><td/><td>&#x0221a;<sup>&#x02020;</sup>
</td></tr><tr><td>&#x02003;Nutrition drink test</td><td/><td>&#x0221a;<sup>*</sup>
</td><td/><td/><td/><td/><td/><td/><td>&#x0221a;<sup>&#x02020;</sup>
</td></tr><tr><td>Intervention</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Acupuncture treatment</td><td/><td>&#x0221a;</td><td>&#x0221a;</td><td>&#x0221a;</td><td>&#x0221a;</td><td>&#x0221a;</td><td>&#x0221a;</td><td>&#x0221a;</td><td>&#x0221a;</td></tr></tbody></table><table-wrap-foot><p>
<sup>*</sup>, conducted before acupuncture treatment; <sup>&#x02020;</sup>, conducted after acupuncture treatment; BDI, Beck Depression Inventory; <italic>AR</italic> Adequate Relief, <italic>VAS</italic> Visual analog scale, <italic>MASS</italic> Massachusetts General Hospital Acupuncture Sensation Scale, <italic>CARE</italic> Consultation and Relational Empathy, <italic>IRI</italic> Interpersonal Reactivty Index, <italic>NDI</italic> Nepean Dyspepsia Index, <italic>SF-36</italic> Short Form 36-item Health Survey, <italic>STAI</italic> State-Trait Anxiety Inventory, <italic>PRISM</italic> Pictorial Representation of Illness and Self Measure</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec19"><title>Sample size calculation</title><p id="Par74">In the present study, we expected a 60% PR from the augmented group and up to a 30% PR from the limited group. These anticipated percentages were derived from previous studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], and a consensus of experts in clinical gastroenterology. Significance was determined as &#x003b1;&#x000a0;=&#x000a0;0.05, and a power of 1 &#x02013; &#x003b2;&#x000a0;=&#x000a0;0.80 was used. Accordingly, the required sample size in this trial was estimated according to the following formula where (p<sub>a</sub>&#x000a0;+&#x000a0;p<sub>l</sub>)/2:<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ n=\frac{{\left({\mathrm{Z}}_{\upalpha /2}\sqrt{2\overline{p}\left(12\overline{p}\right)}+ Z\beta \sqrt{p_a\left(1-{p}_a\right)+{p}_l\left(1-{p}_l\right)}\right)}^2}{{\left({p}_a-{p}_l\right)}^2} $$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi mathvariant="normal">Z</mml:mi><mml:mrow><mml:mi mathvariant="normal">&#x003b1;</mml:mi><mml:mo stretchy="true">/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msqrt><mml:mrow><mml:mn>2</mml:mn><mml:mover accent="false"><mml:mi>p</mml:mi><mml:mo>&#x000af;</mml:mo></mml:mover><mml:mfenced close=")" open="("><mml:mrow><mml:mn>12</mml:mn><mml:mover accent="false"><mml:mi>p</mml:mi><mml:mo>&#x000af;</mml:mo></mml:mover></mml:mrow></mml:mfenced></mml:mrow></mml:msqrt><mml:mo>+</mml:mo><mml:mi mathvariant="italic">Z&#x003b2;</mml:mi><mml:msqrt><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>l</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:msqrt></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:msub><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mi>p</mml:mi></mml:mrow><mml:mi>l</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:mfrac></mml:math><graphic xlink:href="12906_2017_1869_Article_Equa.gif" position="anchor"/></alternatives></disp-formula>
</p><p id="Par75">Assuming p<sub>a</sub>&#x000a0;=&#x000a0;0.6 (p<sub>a</sub>: the effect on the augmented group) and p<sub>l</sub>&#x000a0;=&#x000a0;0.3 (p<sub>l</sub>: the effect on the limited group), a sample size of <italic>n</italic>&#x000a0;=&#x000a0;40 is calculated to achieve 5% significance level and 80% power. Assuming a dropout rate of 10%, a total of 88 participants were needed with a 1:1 allocation to each group (44 participants per group).</p></sec><sec id="Sec20"><title>Statistical analysis</title><p id="Par76">To compare demographic or clinical characteristics a two-sample <italic>t</italic>-test (in case of continuous data) or Chi-square test (in case of binary data) will be used. If a significant difference is identified between the augmented and limited groups, a general linear model-analysis of covariance will be used for continuous data, and logistic regression analysis will be used for binary data. To compare the mean value of two groups, a two-sample <italic>t</italic>-test will be used as a parametric method, and Mann-Whitney test will be used as a non-parametric method. The paired <italic>t</italic>-test will be used as parametric method and Wilcoxon signed ranks test will be used as non-parametric method to compare variables before and after intervention. The repeated measured <italic>t</italic>-test will be used to compare the mean value of variables between the two groups. A <italic>P</italic> value of &#x0003c;0.05 will be considered as statistical significance. Efficacy will be investigated as the difference between baseline (1&#x000a0;week) and the completion of treatment (4&#x000a0;weeks). To assess the efficacy of interventions, both intention to treat and per-protocol analysis will be performed. Participants who complete the clinical trial without any violations are targeted in per-protocol analysis. Statistical analysis other than described above will follow Guideline for Clinical Trial Statistics (Article No. 65615&#x02013;13,553, December 29th 2000).</p></sec><sec id="Sec21"><title>Safety</title><p id="Par77">Adverse events related to acupuncture treatment, including swelling, pain, bruising at the insertion site, discomfort, and dizziness will be assessed and recorded by Clinical Research Coordinator. Research physicians will manage adverse events, and the principle investigator will be notified. In the event of serious adverse events, the IRB and the sponsor will be notified within 24&#x000a0;h, regardless of causality. The principle investigator has the right terminate the study if serious adverse events occur.</p></sec><sec id="Sec22"><title>Quality control</title><p id="Par78">To confirm the quality of the study, all practitioners of acupuncture will be required to have a license and more than 2 years of experience. To improve consistency, all researchers will be trained several times in both the augmented and limited context. Outcome measurements are retained in the source documents, the hospital or private records, and the laboratory results and records. Original data in source documents will be recorded into the electronic Case Report Form (e-CRF). The data entered into the e-CRF will be identical to the original data. Independent investigators and the Clinical Research Coordinator will verify the accuracy of the data in the e-CRF, and an independent statistician will analyze the data. If participants do not complete the study, the reasons will be fully documented.</p></sec><sec id="Sec23"><title>Monitoring</title><p id="Par79">Monitoring will be carried out to assess whether the documents are accurate and precise in comparison with the reference, and that the study is performed in accordance with the approved protocol and regulations. A monitoring agent, designated by the sponsor, will be responsible for monitoring throughout the study. The principal investigator will provide source documents to monitoring agent. Monitoring includes review of e-CRF and informed consent forms.</p></sec></sec><sec id="Sec24"><title>Discussion</title><p id="Par80">This study will provide information about the influence of patient-practitioner interaction on the effect of acupuncture in functional dyspepsia, and increase the knowledge about the placebo effect on complementary and alternative medicine treatments in functional gastrointestinal diseases. This study will also compare the non-specific effects of the patient-practitioner relationship between Asian patients, with familiarity of acupuncture, and Western patients, who may not be familiar with acupuncture. We will investigate the participants&#x02019; experience and use of complementary and alternative medicine at the baseline. The results of this study will be published regardless of outcome in an article on accordance of STRICTA guidelines.</p><sec id="Sec25"><title>Trial status</title><p id="Par81">Recruitment began in February 2017.</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CARE</term><def><p id="Par5">Consultation and Relational Empathy</p></def></def-item><def-item><term>e-CRF</term><def><p id="Par6">Electronic Case Report Form</p></def></def-item><def-item><term>FD</term><def><p id="Par7">Functional dyspepsia</p></def></def-item><def-item><term>IRB</term><def><p id="Par8">Institutional Review Board</p></def></def-item><def-item><term>IRI</term><def><p id="Par9">Interpersonal Reactivity Index</p></def></def-item><def-item><term>LI</term><def><p id="Par10">Large intestine meridian</p></def></def-item><def-item><term>LR</term><def><p id="Par11">Liver meridian</p></def></def-item><def-item><term>MASS</term><def><p id="Par12">The Massachusetts General Hospital Acupuncture Sensation Scale</p></def></def-item><def-item><term>NDI</term><def><p id="Par13">The Nepean Dyspepsia Index</p></def></def-item><def-item><term>PC</term><def><p id="Par14">Pericardium meridian</p></def></def-item><def-item><term>PR</term><def><p id="Par15">Proportion of responder</p></def></def-item><def-item><term>PRISM</term><def><p id="Par16">The Pictorial Representation of Illness and Self Measure</p></def></def-item><def-item><term>SF-36</term><def><p id="Par17">The Short Form 36-item Health Survey</p></def></def-item><def-item><term>SP</term><def><p id="Par18">Spleen meridian</p></def></def-item><def-item><term>ST</term><def><p id="Par19">Stomach meridian</p></def></def-item><def-item><term>STAI</term><def><p id="Par20">The State-Trait Anxiety Inventory</p></def></def-item><def-item><term>STRICTA</term><def><p id="Par21">STandards for Reporting Interventions in Clinical Trials of Acupuncture</p></def></def-item><def-item><term>VAS</term><def><p id="Par22">Visual analogue scale</p></def></def-item></def-list></glossary><ack><p>This study was supported by the Traditional Korean Medicine R&#x00026;D program funded by the Ministry of Health &#x00026; Welfare through the Korea Health Industry Development Institute (KHIDI) (HI13C0700).</p><sec id="FPar12"><title>Availability of data and materials</title><p id="Par82">Not applicable.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>SJK wrote the study protocol and drafted this manuscript. JWP participated in the conception and design of the trial. J Leem participated in the design of the trial and quality control. TJK contributed to design of the protocol and conception of the trial. VN participated in conception and design of the trial. BK participated in design and coordination of the trial. JG participated in design and acupuncture practice. LD participated in building conception of the trial and quality control. IY participated in the design of statistical analysis and sample size calculation. J Lee monitored the trial and carried out the statistical analysis. JK participated in drafting and proofreading the manuscript. J Lee and JK are the corresponding authors. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar13"><title>Ethics approval and consent to participate</title><p id="Par83">This trial will be carried out according to the standards of the International Committee on Harmonization on Good Clinical Practice and the Declaration of Helsinki. Medical Ethics Committee at KyungHee University Hospital at Gangdong (approval number is KHNMCOH 2016-04-007-001), Kyung Hee University Medical Center (No. KOMCIRB &#x02013; 150914 &#x02013; HR - 040), and Massachusetts General Hospital (No. 2016P001981/PHS) have approved this protocol. Informed consent will be gained from all participants before commencing the trial.</p></sec><sec id="FPar14"><title>Consent for publication</title><p id="Par84">Not applicable.</p></sec><sec id="FPar15"><title>Competing interests</title><p id="Par85">The authors declare that they have no competing interests.</p></sec><sec id="FPar16"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drossman</surname><given-names>DA</given-names></name></person-group><article-title>The functional gastrointestinal disorders and the Rome III process</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><fpage>1377</fpage><lpage>1390</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2006.03.008</pub-id><pub-id pub-id-type="pmid">16678553</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Lacy BE, Talley NJ, Locke GR 3rd, Bouras EP, DiBaise JK, El-Serag HB, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther. 2012;36(1):3&#x02013;15.</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>JD</given-names></name></person-group><article-title>Review article: therapeutic roles of acupuncture in functional gastrointestinal disorders</article-title><source>Aliment Pharmacol Ther</source><year>2004</year><volume>20</volume><fpage>831</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2004.02196.x</pub-id><pub-id pub-id-type="pmid">15479354</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaptchuk</surname><given-names>TJ</given-names></name></person-group><article-title>Powerful placebo: the dark side of the randomized controlled trial</article-title><source>Lancet</source><year>1998</year><volume>351</volume><fpage>1722</fpage><lpage>1725</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(97)10111-8</pub-id><pub-id pub-id-type="pmid">9734904</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hrobjartsson</surname><given-names>A</given-names></name></person-group><article-title>What are the main methodological problems in the estimation of placebo effects</article-title><source>J Clin Epidemiol</source><year>2002</year><volume>55</volume><fpage>430</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1016/S0895-4356(01)00496-6</pub-id><pub-id pub-id-type="pmid">12007544</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>FG</given-names></name><name><surname>Kaptchuk</surname><given-names>TJ</given-names></name></person-group><article-title>The power of context: reconceptualizing the placebo effect</article-title><source>J R Soc Med</source><year>2008</year><volume>101</volume><issue>5</issue><fpage>222</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1258/jrsm.2008.070466</pub-id><pub-id pub-id-type="pmid">18463276</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savarino</surname><given-names>V</given-names></name><name><surname>Savarino</surname><given-names>E</given-names></name><name><surname>Parodi</surname><given-names>A</given-names></name><name><surname>Dulbecco</surname><given-names>P</given-names></name></person-group><article-title>Functional heartburn and non-erosive reflux disease</article-title><source>Dig Dis</source><year>2007</year><volume>25</volume><issue>3</issue><fpage>172</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1159/000103879</pub-id><pub-id pub-id-type="pmid">17827934</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veldhuyzen van Zanten</surname><given-names>SJ</given-names></name><name><surname>Cleary</surname><given-names>C</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Peterson</surname><given-names>TC</given-names></name><name><surname>Nyr&#x000e9;n</surname><given-names>O</given-names></name><name><surname>Bradley</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials</article-title><source>Am J Gastroenterol</source><year>1996</year><volume>91</volume><issue>4</issue><fpage>660</fpage><lpage>673</lpage><pub-id pub-id-type="pmid">8677926</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaptchuk</surname><given-names>TJ</given-names></name><name><surname>Kelley</surname><given-names>JM</given-names></name><name><surname>Conboy</surname><given-names>LA</given-names></name><name><surname>Davis</surname><given-names>RB</given-names></name><name><surname>Kerr</surname><given-names>CE</given-names></name><name><surname>Jacobson</surname><given-names>EE</given-names></name><etal/></person-group><article-title>Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome</article-title><source>BMJ</source><year>2008</year><volume>336</volume><issue>7651</issue><fpage>999</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1136/bmj.39524.439618.25</pub-id><pub-id pub-id-type="pmid">18390493</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dossett</surname><given-names>ML</given-names></name><name><surname>Mu</surname><given-names>L</given-names></name><name><surname>Davis</surname><given-names>RB</given-names></name><name><surname>Bell</surname><given-names>IR</given-names></name><name><surname>Lembo</surname><given-names>AJ</given-names></name><name><surname>Kaptchuk</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Patient-provider interactions affect symptoms in Gastroesophageal reflux disease: a pilot randomized, double-blind, placebo-controlled trial</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>9</issue><fpage>e0136855</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0136855</pub-id><pub-id pub-id-type="pmid">26422466</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>HM</given-names></name></person-group><article-title>A standardization study of Beck depression inventory in Korea</article-title><source>Kor J Psycho</source><year>1986</year><volume>76</volume><fpage>487</fpage><lpage>502</lpage></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacPherson</surname><given-names>H</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Hammerschlag</surname><given-names>R</given-names></name><name><surname>Youping</surname><given-names>L</given-names></name><name><surname>Taixiang</surname><given-names>W</given-names></name><name><surname>White</surname><given-names>A</given-names></name><etal/></person-group><article-title>Revised STandards for reporting interventions in clinical trials of acupuncture (STRICTA): extending the CONSORT statement</article-title><source>PLoS Med</source><year>2010</year><volume>7</volume><issue>6</issue><fpage>e1000261</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1000261</pub-id><pub-id pub-id-type="pmid">20543992</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Van Zanten</surname><given-names>SV</given-names></name><name><surname>Saez</surname><given-names>LR</given-names></name><name><surname>Dukes</surname><given-names>G</given-names></name><name><surname>Perschy</surname><given-names>T</given-names></name><name><surname>Heath</surname><given-names>M</given-names></name><etal/></person-group><article-title>A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia</article-title><source>Aliment Pharmacol Ther</source><year>2001</year><volume>15</volume><issue>4</issue><fpage>525</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2001.00941.x</pub-id><pub-id pub-id-type="pmid">11284782</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>SJ</given-names></name><name><surname>Kuo</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>SK</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><etal/></person-group><article-title>Individualized acupuncture for symptom relief in functional dyspepsia: a randomized controlled trial</article-title><source>J Altern Complement Med</source><year>2016</year><volume>22</volume><issue>12</issue><fpage>997</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.1089/acm.2016.0208</pub-id><pub-id pub-id-type="pmid">27732083</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Haque</surname><given-names>M</given-names></name><name><surname>Wyeth</surname><given-names>JW</given-names></name><name><surname>Stace</surname><given-names>NH</given-names></name><name><surname>Tytgat</surname><given-names>GN</given-names></name><name><surname>Stanghellini</surname><given-names>V</given-names></name><etal/></person-group><article-title>Development of a new dyspepsia impact scale: the Nepean dyspepsia index</article-title><source>Aliment Pharmacol Ther</source><year>1999</year><volume>13</volume><fpage>225</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.1999.00445.x</pub-id><pub-id pub-id-type="pmid">10102954</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Choi</surname><given-names>SC</given-names></name><name><surname>Cho</surname><given-names>YK</given-names></name><name><surname>Choi</surname><given-names>MG</given-names></name></person-group><article-title>Validation of the Nepean dyspepsia index - Korean version</article-title><source>Kor J Neurogastroenterol Mot</source><year>2003</year><volume>9</volume><issue>suppl</issue><fpage>48S</fpage></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Sherbourne</surname><given-names>CD</given-names></name></person-group><article-title>The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection</article-title><source>Med Care</source><year>1992</year><volume>30</volume><fpage>473</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1097/00005650-199206000-00002</pub-id><pub-id pub-id-type="pmid">1593914</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>CW</given-names></name><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Iwaya</surname><given-names>T</given-names></name><name><surname>Kataoka</surname><given-names>H</given-names></name><name><surname>Kohzuki</surname><given-names>M</given-names></name></person-group><article-title>Development of the Korean version of short-form 36-item health survey: health related QOL of healthy elderly people and elderly patients in Korea</article-title><source>Tohoku J Exp Med</source><year>2004</year><volume>203</volume><issue>3</issue><fpage>189</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1620/tjem.203.189</pub-id><pub-id pub-id-type="pmid">15240928</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Spielberger</surname><given-names>CD</given-names></name><name><surname>Goursuch</surname><given-names>RL</given-names></name><name><surname>Lushene</surname><given-names>RE</given-names></name></person-group><source>Manual for the state trait anxiety inventory</source><year>1983</year><publisher-loc>Mountain View</publisher-loc><publisher-name>Consulting Psychologist Press</publisher-name></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miwa</surname><given-names>H</given-names></name><name><surname>Nagahara</surname><given-names>A</given-names></name><name><surname>Tominaga</surname><given-names>K</given-names></name><name><surname>Yokoyama</surname><given-names>T</given-names></name><name><surname>Sawada</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><etal/></person-group><article-title>Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial</article-title><source>Am J Gastroenterol</source><year>2009</year><volume>104</volume><issue>11</issue><fpage>2779</fpage><lpage>2787</lpage><pub-id pub-id-type="doi">10.1038/ajg.2009.427</pub-id><pub-id pub-id-type="pmid">19638966</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Futagami</surname><given-names>S</given-names></name><name><surname>Yamawaki</surname><given-names>H</given-names></name><name><surname>Izumi</surname><given-names>N</given-names></name><name><surname>Shimpuku</surname><given-names>M</given-names></name><name><surname>Kodaka</surname><given-names>Y</given-names></name><name><surname>Wakabayashi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Impact of sleep disorders in Japanese patients with functional dyspepsia (FD): nizatidine improves clinical symptoms, gastric emptying and sleep disorders in FD patients</article-title><source>J Gastroenterol Hepatol</source><year>2013</year><volume>28</volume><issue>8</issue><fpage>1314</fpage><lpage>1320</lpage><pub-id pub-id-type="doi">10.1111/jgh.12236</pub-id><pub-id pub-id-type="pmid">23611167</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>J</given-names></name><name><surname>Gollub</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>T</given-names></name><name><surname>Polich</surname><given-names>G</given-names></name><name><surname>Napadow</surname><given-names>V</given-names></name><name><surname>Hui</surname><given-names>K</given-names></name><etal/></person-group><article-title>Acupuncture de qi, from qualitative history to quantitative measurement</article-title><source>J Altern Complement Med</source><year>2007</year><volume>13</volume><fpage>1059</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1089/acm.2007.0524</pub-id><pub-id pub-id-type="pmid">18166116</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercer</surname><given-names>SW</given-names></name><name><surname>Maxwell</surname><given-names>M</given-names></name><name><surname>Heaney</surname><given-names>D</given-names></name><name><surname>Watt</surname><given-names>GC</given-names></name></person-group><article-title>The consultation and relational empathy (CARE) measure: development and preliminary validation and reliability of an empathy based consulation process measure</article-title><source>Fam Pract</source><year>2004</year><volume>21</volume><issue>6</issue><fpage>699</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1093/fampra/cmh621</pub-id><pub-id pub-id-type="pmid">15528286</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>MH</given-names></name></person-group><article-title>Measuring individual differences in empathy: evidence for a multi dimensional approach</article-title><source>J Pers Soc Psychol</source><year>1983</year><volume>44</volume><fpage>113</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1037/0022-3514.44.1.113</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>I</given-names></name><name><surname>Kee</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Jung</surname><given-names>B</given-names></name><name><surname>Hwang</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><etal/></person-group><article-title>Reliability and validity of the Korean-version of interpersonal reactivity index</article-title><source>Kor J Psychol</source><year>2009</year><volume>48</volume><issue>5</issue><fpage>352</fpage><lpage>358</lpage></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>B</given-names></name><name><surname>Camilleri</surname><given-names>M</given-names></name><name><surname>Burton</surname><given-names>D</given-names></name><name><surname>Viramontes</surname><given-names>B</given-names></name><name><surname>McKinzie</surname><given-names>S</given-names></name><name><surname>Thomforde</surname><given-names>G</given-names></name><etal/></person-group><article-title>Effects of 5-HT(3) antagonism on postprandial gastric volume and symptoms in humans</article-title><source>Aliment Pharmacol Ther</source><year>2002</year><volume>16</volume><issue>2</issue><fpage>225</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2002.01144.x</pub-id><pub-id pub-id-type="pmid">11860405</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iida</surname><given-names>A</given-names></name><name><surname>Kaneko</surname><given-names>H</given-names></name><name><surname>Konagaya</surname><given-names>T</given-names></name><name><surname>Kasugai</surname><given-names>K</given-names></name></person-group><article-title>How to interpret a functional or motility test - slow nutrient drinking test</article-title><source>J Neurogastroenterol Motil</source><year>2012</year><volume>18</volume><issue>3</issue><fpage>332</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.5056/jnm.2012.18.3.332</pub-id><pub-id pub-id-type="pmid">22837882</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Elzen</surname><given-names>BD</given-names></name><name><surname>Bennink</surname><given-names>RJ</given-names></name><name><surname>Holman</surname><given-names>R</given-names></name><name><surname>Tytgat</surname><given-names>GN</given-names></name><name><surname>Boeckxstaens</surname><given-names>GE</given-names></name></person-group><article-title>Impaired drinking capacity in patients with functional dyspepsia: intragastric distribution and distal stomach volume</article-title><source>Neurogastroenterol Motil</source><year>2007</year><volume>19</volume><issue>12</issue><fpage>968</fpage><lpage>976</lpage><pub-id pub-id-type="pmid">17973641</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peter</surname><given-names>N</given-names></name><name><surname>Kleinjung</surname><given-names>T</given-names></name><name><surname>Horat</surname><given-names>L</given-names></name><name><surname>Schmidt-Weitmann</surname><given-names>S</given-names></name><name><surname>Meyer</surname><given-names>M</given-names></name><name><surname>B&#x000fc;chi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Validation of PRISM (pictorial representation of illness and self measure) as a novel visual assessment tool for the burden of suffering in tinnitus patients</article-title><source>Health Qual Life Outcomes</source><year>2016</year><volume>14</volume><fpage>47</fpage><pub-id pub-id-type="doi">10.1186/s12955-016-0454-2</pub-id><pub-id pub-id-type="pmid">27001548</pub-id></element-citation></ref></ref-list></back></article>